Core Viewpoint - Kingsray Biotechnology (01548) reported a significant increase in revenue and a reduction in losses for the six months ending June 30, 2025, indicating strong operational performance and strategic investments in innovation and marketing [1] Financial Performance - Revenue from continuing operations reached $519 million, an increase of 81.92% year-on-year [1] - Loss attributable to equity holders narrowed to $25.462 million, a reduction of 85.46% year-on-year [1] - Basic loss per share was 1.18 cents [1] Segment Performance - Revenue from life sciences services and products was approximately $248 million, up 11.3% from about $222 million in the previous period [1] - Adjusted gross profit was approximately $126 million, an increase of 5.3% from about $120 million [1] - Adjusted gross margin slightly decreased from 53.9% to 51.0% [1] - Adjusted operating profit decreased slightly from approximately $47.8 million to about $46.4 million [1] Growth Drivers - Revenue and adjusted gross profit growth were primarily driven by: - Platform innovation and automation upgrades, particularly in protein and gene editing platforms, leading to reliable, fast, and high-quality service and product delivery [1] - Enhanced operational efficiency at production bases in mainland China, Singapore, and the United States [1] - Targeted activities and brand revitalization efforts to improve customer engagement [1] - The decrease in adjusted operating profit was attributed to increased investments in marketing transformation and research and development activities aimed at building long-term competitiveness [1]

Financial Data and Key Metrics Changes - Q2 GAAP revenue was $27 million, up from $21 million in Q1 2025 and $25 million in Q2 2024, reflecting a 30% sequential increase and an 8% year-over-year increase [5][16] - Excluding one-time adjustments, revenue grew 22% quarter-over-quarter and 4% year-over-year [5][16] - Q2 adjusted EBITDA loss was $10 million, an improvement from a loss of $16 million in Q1 2025 and a loss of $13 million in Q2 2024, representing a 36% improvement quarter-over-quarter and 17% year-over-year [6][18] - Q2 net loss was $9 million compared to a net income of $26 million in the same quarter last year, with an adjusted EBITDA loss improving by $3 million year-over-year [18] Business Line Data and Key Metrics Changes - Paying Monthly Active Users (MAU) reached 146,000, up from 124,000 in Q1 2025 and 122,000 in Q2 2024, indicating an 18% growth quarter-over-quarter and 20% growth year-over-year [5][16] - The paid user conversion rate increased to 19% in Q2 from 15% a year ago [17] Market Data and Key Metrics Changes - User acquisition marketing expenses in Q2 were $3 million, while engagement marketing expenses were $9 million, with total sales and marketing expenses down 16% year-over-year [17] Company Strategy and Development Direction - The company is focused on enhancing its platform to improve player and developer engagement, with significant progress made in loyalty programs and user experience [6][7] - A three-year commitment of $75 million has been made to support a developer accelerator program, aimed at encouraging game development for the platform [9] - The company is also pursuing litigation against competitors for alleged unfair practices, emphasizing its commitment to fair competition [14][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to achieve positive adjusted EBITDA and highlighted the steady strides being made towards profitability [11][12] - The company believes its current valuation does not reflect the combined value of its operating platform and progress made [15] Other Important Information - The company is working to complete its financial statements for the year ended December 31, 2024, after receiving a notice from the NYSE regarding non-compliance with listing standards [3] - The company ended Q2 with $239 million in cash, providing flexibility to enhance shareholder value [19] Q&A Session Summary - No questions were registered during the Q&A session, and the call concluded without further inquiries [20]